ArticleBritish journal of cancer2013
The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.Molecular oncology · 2021Trial
- High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia.Blood · 2015Trial
- Overexpression of MIEN1 in Oral Squamous Cell Carcinoma: Correlation with Tumor Invasion and Lymph Node Metastasis.Journal of dentistry (Shiraz, Iran) · 2026Article
- TAp73 represses NF-κB-mediated recruitment of tumor-associated macrophages in breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Article
- PRSS1 Upregulation Predicts Platinum Resistance in Ovarian Cancer Patients.Frontiers in cell and developmental biology · 2020Article
- Article
- Emerging Role of Migration and Invasion Enhancer 1 (MIEN1) in Cancer Progression and Metastasis.Frontiers in oncology · 2019Review
- Emerging targets in cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Article
- Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.BMC cancer · 2018Review
- ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype.Oncotarget · 2017Article
- MIEN1 is tightly regulated by SINE Alu methylation in its promoter.Oncotarget · 2016Article
- MIEN1 drives breast tumor cell migration by regulating cytoskeletal-focal adhesion dynamics.Oncotarget · 2016Article
- Overexpression of the ∆Np73 isoform is associated with centrosome amplification in brain tumor cell lines.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.Oncogene · 2015Review
- Oncogenes associated with drug resistance in ovarian cancer.Journal of cancer research and clinical oncology · 2015Review
- TAp73 suppresses tumor angiogenesis through repression of proangiogenic cytokines and HIF-1α activity.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- MIEN1 promotes oral cancer progression and implicates poor overall survival.Cancer biology & therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to characterise the oncogenic roles of C35, a novel protein binding partner of ΔNp73, in ovarian cancer and to investigate the functional significance of C35-ΔNp73 interaction in the regulation of chemo-resistance.
methodsC35 expression was evaluated by quantitative real-time PCR in human ovarian cancer tissues and cell lines. The aggressiveness of ovarian cancer cells overexpressing C35 was examined by cell proliferation, migration, soft agar and nude mouse xenograft. The significance of C35-ΔNp73 interaction in chemo-resistance was evaluated by apoptosis assays and cell viability after cisplatin treatment.
resultsThe expression of C35 was significantly enhanced in human ovarian cancer tissues. Overexpression of C35 augmented proliferation, migration and tumourigenicity in ovarian cancer cell lines. C35 knockdown inhibited cell motility and cell growth. The co-expression of C35 and ΔNp73 by transient or stable transfection in ovarian cancer cells induced greater resistance to cisplatin treatment than did transfection with C35 or ΔNp73 alone. The cisplatin resistance was demonstrated to be caused by increased AKT and NFκB activity induced by C35-ΔNp73.
conclusionOur results suggest that ΔNp73 might cooperate with C35 to promote tumour progression and contribute to cisplatin resistance in ovarian cancer cells. Future studies of the functional roles of ΔNp73 and C35 will provide insight that will aid in the establishment of new strategies and more effective therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.